Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study

Trial Profile

Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs ALLN 177 (Primary)
  • Indications Hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms URIROX-1
  • Sponsors Allena Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 06 Mar 2018 According to an Allena Pharmaceuticals media release, initiation of this trial triggers submission of the protocol for FDA review for comments on the protocol.
    • 06 Mar 2018 This trial is being conducted under planned Biologic License Application (BLA), as reported in an Allena Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top